Literature DB >> 15501728

Targeting JNK3 for the treatment of neurodegenerative disorders.

Lynn Resnick1, Myles Fennell.   

Abstract

c-Jun N-terminal kinases (JNKs) have been recognized as important enzymes in cellular function. JNK3, which is predominantly found in CNS neurons, has been implicated in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and stroke. In particular, JNK3 has been found to have an upstream role in neuronal ischemic apoptosis. JNK3 is highly expressed and activated in postmortem brains of individuals that suffered from Alzheimer's disease. Furthermore, mice that are deficient in JNK3 are more resistant to 1-methyl-4-phenyl-1,2,4,6-tetrahydropyridine (a neurotoxin that mimics the neuropathological characteristics of Parkinson's disease) than their wild-type littermates. Because of the involvement of JNK3 in neuronal diseases, the inhibition of this enzyme is an attractive therapeutic target.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15501728     DOI： 10.1016/S1359-6446(04)03251-9

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  29 in total

1.  c-Jun N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity.

Authors:  Chieko Saito; John J Lemasters; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2010-04-25       Impact factor: 4.219

2.  Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.

Authors:  Romain Noël; Youseung Shin; Xinyi Song; Yuanjun He; Marcel Koenig; Weimin Chen; Yuan Yuan Ling; Li Lin; Claudia H Ruiz; Phil LoGrasso; Michael D Cameron; Derek R Duckett; Theodore M Kamenecka
Journal:  Bioorg Med Chem Lett       Date:  2010-12-01       Impact factor: 2.823

Review 3.  The c-jun kinase/stress-activated pathway: regulation, function and role in human disease.

Authors:  Gary L Johnson; Kazuhiro Nakamura
Journal:  Biochim Biophys Acta       Date:  2007-01-04

Review 4.  Unique MAP Kinase binding sites.

Authors:  Radha Akella; Thomas M Moon; Elizabeth J Goldsmith
Journal:  Biochim Biophys Acta       Date:  2007-11-19

5.  Molecular and bioenergetic differences between cells with African versus European inherited mitochondrial DNA haplogroups: implications for population susceptibility to diseases.

Authors:  M Cristina Kenney; Marilyn Chwa; Shari R Atilano; Payam Falatoonzadeh; Claudio Ramirez; Deepika Malik; Mohamed Tarek; Javier Cáceres Del Carpio; Anthony B Nesburn; David S Boyer; Baruch D Kuppermann; Marquis P Vawter; S Michal Jazwinski; Michael V Miceli; Douglas C Wallace; Nitin Udar
Journal:  Biochim Biophys Acta       Date:  2013-11-04

6.  c-Jun N-terminal kinase inhibitor SP600125 modulates the period of mammalian circadian rhythms.

Authors:  M Chansard; P Molyneux; K Nomura; M E Harrington; C Fukuhara
Journal:  Neuroscience       Date:  2007-01-30       Impact factor: 3.590

Review 7.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

8.  Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Tracey S Hanks; Irina Kochetkova; David W Pascual; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2012-03-20       Impact factor: 4.436

9.  Arrestin-dependent activation of JNK family kinases.

Authors:  Xuanzhi Zhan; Seunghyi Kook; Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014

10.  An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS).

Authors:  Salvador Harguindey; Gorka Orive; Ramón Cacabelos; Enrique Meléndez Hevia; Ramón Díaz de Otazu; Jose Luis Arranz; Eduardo Anitua
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.